UCL spinout Promethera Biosciences has received $11.3m in series D funding from Itochu and $16.6m in a convertible debt round backed by Sosei.

Conglomerate Itochu has agreed to provide €10m ($11.3m) in capital as anchor investor in a series D round being raised by Promethera Biosciences, a Belgium-based liver disease therapy spinout of Université catholique de Louvain. The company disclosed the investment alongside $16.6m in convertible bond financing from investors including biopharmaceutical company Sosei Group, Beyond Next Ventures,…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.